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OBJECTIVES: Type-2 diabetes patients with hypertension have
a high risk of developing nephropathy, with increased risks of
morbidity/mortality. Screening for, and treatment of nephropa-
thy, is currently suboptimal in France. We assessed the long-term
impact of screening for nephropathy followed by optimal anti-
hypertensive therapy in those in which nephropathy is detected
in France. METHODS: A Markov model projected lifetime
impacts of screening, identiﬁcation, and appropriate treatment
of nephropathy using semi-quantitative urine dipsticks in a
primary care setting, followed by treatment with irbesartan 300
mg added to conventional antihypertensives in a typical cohort
of hypertensive Type-2 diabetes patients. The model simulated
progression from no renal disease to end-stage renal disease
(ESRD). Probabilities and costs came from published sources.
Cumulative incidence of ESRD, years free of ESRD, life
expectancy (LE) and direct costs were projected. Second-order
Monte Carlo simulation was used to account for uncertainty in
multiple parameters. RESULTS: In a cohort of 1000 patients,
screening for nephropathy followed by optimal treatment
reduced cumulative incidence of ESRD from (mean ± SD) 11.0
± 1.7% to 6.5 ± 1.1%, increased number of ESRD-free years by
524 ± 80 years, increased undiscounted LE by 361 ± 60 years,
and reduced costs (discounted 3% annually) by €3,340,200 ±
799,800. Sensitivity analysis showed that screening was most
beneﬁcial in younger patients. CONCLUSIONS: In hypertensive
type-2 diabetes patients, screening for albuminuria followed by
optimal antihypertensive treatment that includes irbesartan 300
mg, is projected to lead to substantial reductions in the incidence
of ESRD, improvements in ESRD-free survival and life
expectancy, and overall cost savings.
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OBJECTIVE: Diabetes mellitus is an important chronic disease
with a growing prevalence that absorbs an ever increasing invest-
ment of resources. This study described the prevalence and the
cost of diabetic care using sampling claim data from the National
Health Insurance Program in Taiwan. METHOD: Five-year
(1997~2001) random sampling claimed database were prepared
by the National Health Research Institute, Taiwan, R.O.C. The
database contains 200,000 individuals’ longitudinal medical
claim data (0.9% Taiwan population), including outpatient and
inpatient care records. Patients with the ICD-9-CM code of 250
in their primary diagnosis column were used in the analysis.
RESULT: The prevalence rate of diagnosed diabetes patients
from 1997 to 2001 was 2.42%, 2.57%, 2.61%, 2.67% and
2.74%, respectively. This rate increased 12.8% in 5 years. The
average total direct medical cost per patient per year increased
18%, from 10,479 NTD in 1997 to 12,811 NTD in 2001.The
average number of outpatient visit increased from 7.4 in 1997
to 7.8 times in 2001. The average cost of outpatient care per
patient per year increased 27%, from 7680 NTD in 1997 to
10,016 NTD in 2001. The average inpatient care cost per hos-
pitalization increased 60%, from 29,908 NTD in 1997 to 48,071
NTD in 2001. Finally, the average total drug cost increased 31%,
from 5487 NTD in 1997 to 7209 NTD in 2001. All costs did
not adjust for inﬂation. CONCLUSION: The direct medical cost
for diabetes care increased rapidly in these 5 years, the rate
increased faster then the prevalence rate. The rate of drug cost
increased more then that of the total medical cost. Although the
representative of that sampling data needs veriﬁcation, the pre-
liminary data indicate that outpatient expenditure increased sig-
niﬁcantly. The appropriateness of resource utilization and quality
of diabetes care need more stringent management.
PDB35
THE COST OF DIABETES MELLITUS IN SPAIN
Rubio-Terrés C1, Faure E2, Poyato F3, Del Castillo A3, González P3
1HERO Consulting, Madrid, Spain; 2Hospital Clínico, Zaragoza, Spain;
3Pﬁzer S.A., Spain, Alcobendas, Madrid, Spain
OBJECTIVE: To estimate the cost of diabetes mellitus (DM) in
Spain by reviewing all available DM cost data. METHODS:
Outstanding articles and unpublished data were identiﬁed
through searches of PubMed, Spanish Medical Index, Spanish
databases for doctoral thesis, Ministry of Health, Carlos III
Health Institute, Spanish Health Technology Assessment Agen-
cies, SAMFYC diabetes group, Spanish Federation of Diabetes
Education Societies, and other DM sources from 1966 to
November 2004. All studies with outstanding information on
direct or indirect costs of DM diagnosis, treatment or complica-
tions were included (cost estimates in € of 2004). RESULTS: In
total, 32 cost-of-illness (COI) studies published between 1982
and 2004 met the inclusion criteria (16.354 DM patients), 23 of
them were performed with the prevalence method, 1 with the
incidence method and 6 were pharmacoeconomic analyses. Total
annual costs of DM in Spain would range between €685 and
€2.771 million (1.6–6.4% of the Spanish public health expendi-
ture). However, those results could underestimate the real DM
cost (according to CODE-2 study, the Type-2 DM cost in Spain
would be around 2.317 million € per year). The annual average
cost per patient with DM would range between 1.627 and
€3.982 for DM type-1 and €1.049–€5.091 for DM Type-2. The
cost of hospital admissions, primary care visits and antidiabetic
treatments would be 36–58%, 7–14% and 11–13% of the total
cost, respectively. The indirect costs would be 28–43% of total
DM costs. DM complications costs: serious hypoglycemia
(€3.469), hyperglycemia (€3.357), infections (€2.703), ketoaci-
dosis (€2.633), stroke (€4.091), ischemic cardiac disease
(€3.675), neuropathy (€3.540), nephropathy (€3.525) and
retinopathy (€2.109). CONCLUSIONS: The variability in the
costs estimates was due to the differences of the studies design.
To estimate the real cost of DM, a well designed COI prospec-
tive study is needed.
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OBJECTIVES: Despite the recent increase in incidence and
prevalence of Type-2 diabetes mellitus (T2DM) in Hong Kong,
the economic impact of the disease has never been investigated.
This study aims to estimate the total economic burden of a group
of T2DM patients attending a public hospital in Hong Kong
